Wells Fargo Maintains Equal-Weight on Blueprint Medicines, Raises Price Target to $55
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Derek Archila maintains an Equal-Weight rating on Blueprint Medicines (NASDAQ:BPMC) and raises the price target from $48 to $55.
June 14, 2023 | 12:54 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wells Fargo maintains an Equal-Weight rating on Blueprint Medicines and raises the price target from $48 to $55.
The raised price target by Wells Fargo analyst Derek Archila indicates a positive outlook for Blueprint Medicines. This could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100